November 24, 2025 Dataset Open Access

Mayer, Leonie

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-3" xsi:schemaLocation="http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd">
  <identifier identifierType="DOI">10.25592/uhhfdm.17971</identifier>
  <creators>
    <creator>
      <creatorName>Mayer, Leonie</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7102-4358</nameIdentifier>
      <affiliation>Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Two-year persistence of MERS-CoV-specific antibody and T cell responses  after MVA-MERS-S vaccination in healthy adults</title>
  </titles>
  <publisher>Universität Hamburg</publisher>
  <publicationYear>2025</publicationYear>
  <subjects>
    <subject>vaccine</subject>
    <subject>Modified Vaccinia virus Ankara</subject>
    <subject>Middle East respiratory sydrome coronavirus</subject>
    <subject>immunogenicity</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2025-11-24</date>
  </dates>
  <resourceType resourceTypeGeneral="Dataset"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://www.fdr.uni-hamburg.de/record/17971</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsPartOf">10.25592/uhhfdm.17970</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. &amp;nbsp;Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.&lt;/p&gt;</description>
    <description descriptionType="Other">This dataset includes the immunogenicity data of the manuscript.</description>
  </descriptions>
</resource>